Daou Data (032190) 2026 stock outlook. A qualitative deep dive into the KOSDAQ-listed top holding company of the Daou-Kiwoom group: its double holding structure over Kiwoom Securities, the persistent NAV discount, its IT distribution and VAN/PG payments business, capital allocation, and governance catalysts.
Hanyang Securities (001750) 2026 stock outlook. A qualitative deep dive into this small-cap Korean brokerage: its fixed-income and niche IB model, the Hanyang University foundation stake sale and change of control, its deep-value dividend appeal, and the real estate PF and liquidity risks investors must weigh.
A qualitative 2026 stock outlook for Hyundai Pharm (KRX 004310), the veteran Korean drugmaker behind both a broad ethical-drug portfolio and Mieero Fiber, its decades-old consumer fiber drink. We cover the twin-engine business model, incremental drug pipeline, the low-PBR asset case, owner succession as a re-rating catalyst, drug-price and generic-competition risks, and how global investors should frame the KRW-listed shares.
Daou Tech (KOSPI 023590) 2026 outlook for foreign investors. A deep qualitative look at its Kiwoom Securities stake as the real value driver, the payments and cybersecurity operating business, the chronic holding-company discount, value-up catalysts, plus Korea dividend withholding tax and KRW/USD currency risk.
Bookook Securities (KRX 001270) Stock Outlook 2026 for global investors. Why a bond and proprietary-trading (PI) focused mid-cap Korean broker is a textbook deep-value name — extreme low PBR, a net-cash balance sheet and one of the highest dividend yields on the KOSPI — weighed against bond-valuation earnings swings, rate sensitivity, thin float liquidity and a lack of growth, with peer comparison, three scenarios and the FX and tax angle.
Kyobo Securities (KOSPI 030610) 2026 stock outlook. A deep qualitative look at the mid-cap Korean broker's bond-trading and IB strengths, its appeal as a high-dividend low-PBR value-up candidate, real-estate project-finance (PF) provisioning and funding-cost risk, and how it stacks up against Daishin, Hanwha and Yuanta.
Bukwang Pharmaceutical (KOSPI 003000) 2026 stock analysis: steady generic and improved-drug cash flows, in-house antiviral Levovir (clevudine), the OCI Holdings ownership pivot and value-up angle, Contera Pharma's CNS movement-disorder pipeline, and the binary clinical risk investors must price.
Daehan Synthetic Fiber (KRX 003830) 2026 stock outlook. A Taekwang-group polyester maker whose market cap trades at an extreme discount to net asset value from affiliate stakes, cash, securities and real estate, the value-trap risk from Korean governance and low liquidity, the commodity fiber-spread cycle, and value-up and dividend catalysts analyzed in depth.
HL Holdings (KRX 060980) 2026 stock outlook. A deep qualitative look at the HL Group holding company whose value is chiefly its stake in HL Mando (auto chassis and ADAS), plus HL D and I Halla construction, logistics and an in-house parts-distribution business, the mechanics of the holdco NAV discount, the value-up re-rating case, and the auto-cycle and construction risks that keep the discount wide.
SK Securities (KOSPI: 001510) 2026 stock analysis: a sub-scale Korean brokerage no longer part of SK Group, leaning on IB and real-estate project financing (PF), squeezed by giant full-service rivals and platform brokers. An honest, balanced look at the moat, PF credit risk, low-PBR value-up trades, and what global investors should watch.
Motonic (KOSPI 009680) 2026 stock outlook. A deep dive into the fuel-delivery modules, throttle bodies and LPG/LPi injectors it supplies to Hyundai and Kia, its huge net cash versus tiny market cap, hydrogen FCEV valve optionality, and the EV-transition, single-customer and governance-discount risks.
Hanwha General Insurance (000370) 2026 analysis: how IFRS17 CSM and a shift to long-term protection insurance reshape earnings quality, long-term risk loss ratio, K-ICS capital adequacy, the Carrot pay-per-mile auto insurance option, and deep-value dividend upside versus Samsung Fire and DB Insurance.
Daishin Securities (KRX 003540) Stock Outlook 2026 covering the deep-value mid-cap brokerage and wealth case, Daishin F&I distressed debt (NPLs) and property, the Nine One Hannam luxury development, an extreme low-PBR value-up and high-dividend story, plus trading-volume and real estate PF risk for global investors.
Yuanta Securities Korea (KOSPI 003470) stock outlook for 2026. A qualitative look at the retail brokerage and wealth-management model, sensitivity to trading volumes and rates, the Taiwan-Korea cross-border IB option, the low-PBR value-up dividend angle, small-cap broker risks, and what foreign investors should weigh on KRW FX and withholding tax.
SK Networks (KOSPI 001740) stock outlook for 2026. A qualitative look at the pivot to an 'AI Company' after selling SK Rent-a-car, the hidden real-estate value of Walkerhill, Minttit used-phone kiosks, appliance rental, a global AI-startup portfolio, net cash, buybacks, and the value-up and holding-discount angle.
BNK Financial Group (KRX 138930) Stock Outlook 2026 covering the low-PBR regional bank value case, dividend yield, Korea's value-up program, Busan and Gyeongnam economy exposure, NIM and credit costs for global investors.
JB Financial Group (KRX 175330) stock outlook 2026: a deep dive into Korea's highest-ROE regional financial holding — Jeonbuk Bank, Kwangju Bank and JB Woori Capital — its dividend, value-up program, Cambodia and Southeast Asia exposure, capital efficiency and risks.
Lotte Corp (KRX 004990) Stock Outlook 2026: a practical look at the holding-company NAV discount, Lotte Chemical and Lotte Shopping cycles, dividends, value-up policy, governance, and global-investor tax.
Lotte Shopping (KRX 023530) stock outlook 2026 for global investors: department store premiumization, Lotte On e-commerce struggles, store rationalization, REIT asset monetization, low-PBR value-up, high dividend yield, and consumer cyclicality risks.
SK Inc. (KRX 034730) stock outlook for 2026. A deep qualitative look at Korea's SK Group holding company, its net-asset-value (NAV) of SK Hynix, SK Innovation and SK Telecom stakes, the persistent holding-company discount, HBM upside, the investment-holding-company pivot, dividends and Korea's value-up push.
E-Mart (KRX 139480) stock outlook 2026 for global investors: Korea's #1 hypermarket, Traders warehouse format, SSG.com and Gmarket e-commerce losses, Starbucks Korea stake, hidden real estate value, deep-discount low PBR, the Shinsegae Group value-up turnaround thesis explained.
Samsung Life Insurance 032830 stock outlook 2026 for global investors. We break down its strategically critical Samsung Electronics stake, K-ICS solvency, IFRS17 dynamics, dividend and shareholder-return story, Insurance Business Act stake-valuation and interest-rate risks, and value-up upside.
A 2026 stock outlook for NH Investment & Securities (KRX 005940), analyzing the NongHyup-affiliated broker's IB franchise (ECM, DCM, real estate), high-dividend policy, WM and retail brokerage, bond and trading P&L, real-estate PF exposure risk, the rate cycle, and the Korean value-up re-rating thesis.
A 2026 stock outlook for Hanwha Life (KRX: 088350), one of Korea's life-insurance Big 3, covering the IFRS17 transition and CSM, protection-policy mix, interest-rate sensitivity and asset-liability duration, the K-ICS solvency ratio, the Hanwha Life Financial Services GA channel, dividend resumption odds, demographic risk, and value-up tailwinds for global investors.